Bogdan Haineala1, Anca Zgura2, Camelia Diaconu3, Claudia Mehedintu4, Xenia Bacinschi5, Rodica Maricela Anghel5. 1. Department of Urology, "Fundeni" Clinical Institute, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania. 2. Department of Oncology-Radiotherapy, "Prof. Dr. Alexandru Trestioreanu" Institute of Oncology, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania; medicanca@gmail.com. 3. Department of Internal Medicine, Clinical Emergency Hospital of Bucharest, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania. 4. Department of Obstetrics and Gynecology, Malaxa Clinical Hospital, Bucharest, Romania. 5. Department of Oncology-Radiotherapy, "Prof. Dr. Alexandru Trestioreanu" Institute of Oncology, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Abstract
BACKGROUND/AIM: Kidney cancers account for about 2% of human malignancies. In recent decades, the incidence of this cancer type has gradually increased, mainly due to advances in imaging. The metastatic potential of these cancers is significant: a quarter of patients will immediately present with metastases and more than one third of patients treated with nephrectomy for a localized disease will develop metastases during their course. In total, more than half of patients will suffer from the consequences of metastasis. The median survival at this stage is only thirteen months, so the therapeutic challenge is immense. CASE REPORT: The present case report describes a case of left renal clear cell carcinoma with brain, lung, right adrenal, bone and lymph node metastases in a 55-year-old male. The patient received only one line of anticancer treatment with sunitinib, which could not be continued due to haemorrhagic manifestations in brain metastases. The treatment was changed with immunotherapy which showed its effect even if it was stopped due to the patient wishes in the context of the COVID-19 epidemic. CONCLUSION: Immunotherapy opens the doors to a new era in treatment of metastatic renal cancer and shows efficiency even after it has been stopped. Copyright
BACKGROUND/AIM: Kidney cancers account for about 2% of humanmalignancies. In recent decades, the incidence of this cancer type has gradually increased, mainly due to advances in imaging. The metastatic potential of these cancers is significant: a quarter of patients will immediately present with metastases and more than one third of patients treated with nephrectomy for a localized disease will develop metastases during their course. In total, more than half of patients will suffer from the consequences of metastasis. The median survival at this stage is only thirteen months, so the therapeutic challenge is immense. CASE REPORT: The present case report describes a case of left renal clear cell carcinoma with brain, lung, right adrenal, bone and lymph node metastases in a 55-year-old male. The patient received only one line of anticancer treatment with sunitinib, which could not be continued due to haemorrhagic manifestations in brain metastases. The treatment was changed with immunotherapy which showed its effect even if it was stopped due to the patient wishes in the context of the COVID-19 epidemic. CONCLUSION: Immunotherapy opens the doors to a new era in treatment of metastatic renal cancer and shows efficiency even after it has been stopped. Copyright
Authors: Toni K Choueiri; Mayer N Fishman; Bernard Escudier; David F McDermott; Charles G Drake; Harriet Kluger; Walter M Stadler; Jose Luis Perez-Gracia; Douglas G McNeel; Brendan Curti; Michael R Harrison; Elizabeth R Plimack; Leonard Appleman; Lawrence Fong; Laurence Albiges; Lewis Cohen; Tina C Young; Scott D Chasalow; Petra Ross-Macdonald; Shivani Srivastava; Maria Jure-Kunkel; John F Kurland; Jason S Simon; Mario Sznol Journal: Clin Cancer Res Date: 2016-05-11 Impact factor: 12.531
Authors: Katherine A Murphy; Britnie R James; Yue Guan; Donald S Torry; Andrew Wilber; Thomas S Griffith Journal: Hum Vaccin Immunother Date: 2015 Impact factor: 3.452
Authors: Brian I Rini; Thomas Powles; Michael B Atkins; Bernard Escudier; David F McDermott; Cristina Suarez; Sergio Bracarda; Walter M Stadler; Frede Donskov; Jae Lyun Lee; Robert Hawkins; Alain Ravaud; Boris Alekseev; Michael Staehler; Motohide Uemura; Ugo De Giorgi; Begoña Mellado; Camillo Porta; Bohuslav Melichar; Howard Gurney; Jens Bedke; Toni K Choueiri; Francis Parnis; Tarik Khaznadar; Alpa Thobhani; Shi Li; Elisabeth Piault-Louis; Gretchen Frantz; Mahrukh Huseni; Christina Schiff; Marjorie C Green; Robert J Motzer Journal: Lancet Date: 2019-05-09 Impact factor: 79.321
Authors: James C Yang; Marybeth Hughes; Udai Kammula; Richard Royal; Richard M Sherry; Suzanne L Topalian; Kimberly B Suri; Catherine Levy; Tamika Allen; Sharon Mavroukakis; Israel Lowy; Donald E White; Steven A Rosenberg Journal: J Immunother Date: 2007 Nov-Dec Impact factor: 4.456
Authors: Martin C S Wong; William B Goggins; Benjamin H K Yip; Franklin D H Fung; Colette Leung; Yuan Fang; Samuel Y S Wong; C F Ng Journal: Sci Rep Date: 2017-11-16 Impact factor: 4.379